Okamet-GM 1002 Tablet PR is a combination oral hypoglycemic agent containing Glimepiride 2mg and Metformin 1000mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class drug, stimulates pancreatic beta cells to enhance insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity, contributing to better glycemic control. The combination of these two agents offers complementary mechanisms of action, making Okamet-GM 1002 effective in patients inadequately controlled by diet, exercise, and monotherapy. This formulation is designed for prolonged release, ensuring sustained therapeutic plasma concentrations and improved patient compliance. Okamet-GM 1002 should be administered under medical supervision, with dosage adjustments based on glycemic response and renal function. Common side effects may include gastrointestinal disturbances such as nausea, diarrhea, and abdominal discomfort, which typically diminish with continued use. Caution is advised in patients with renal impairment, hepatic dysfunction, or a history of lactic acidosis. Regular monitoring of blood glucose levels, renal function, and lactic acid is recommended to optimize therapy and minimize adverse effects. Okamet-GM 1002 is a valuable option in the comprehensive management of type 2 diabetes mellitus.